Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Lung Cancer

  Free Subscription


Articles published in Cancer Sci

Retrieve available abstracts of 94 articles:
HTML format
Text format



Single Articles


    July 2018
  1. MURAKAMI H, Nokihara H, Hayashi H, Seto T, et al
    Clinical activity of ASP8273 in Asian patients with non-small cell lung cancer with EGFR activating and T790M mutations.
    Cancer Sci. 2018 Jul 4. doi: 10.1111/cas.13724.
    PubMed     Text format     Abstract available


    June 2018
  2. WATANABE M, Kenmotsu H, Ko R, Wakuda K, et al
    Isolation and molecular analysis of circulating tumor cells from lung cancer patients using a microfluidic chip type cell sorter.
    Cancer Sci. 2018 Jun 14. doi: 10.1111/cas.13692.
    PubMed     Text format     Abstract available


  3. QIN T, Huang D, Liu Z, Zhang X, et al
    TNFSF15 promotes lymphatic metastasis via up-regulation of VEGFC in a mouse model of lung cancer.
    Cancer Sci. 2018 Jun 11. doi: 10.1111/cas.13665.
    PubMed     Text format     Abstract available


  4. WANG H, Zhang G
    Endoplasmic reticulum stress-mediated autophagy protects against beta,beta-dimethylacrylshikonin-induced apoptosis in lung adenocarcinoma cells.
    Cancer Sci. 2018;109:1889-1901.
    PubMed     Text format     Abstract available


  5. ALAEE M, Nool K, Pasdar M
    Plakoglobin restores tumor suppressor activity of p53(R175H) mutant by sequestering the oncogenic potential of beta-catenin.
    Cancer Sci. 2018;109:1876-1888.
    PubMed     Text format     Abstract available


  6. FENG W, Xie Q, Liu S, Ji Y, et al
    Kruppel-like factor 4 promotes c-Met amplification-mediated gefitinib resistance in non-small-cell lung cancer.
    Cancer Sci. 2018;109:1775-1786.
    PubMed     Text format     Abstract available


    May 2018
  7. AZUMA K, Nishio M, Hayashi H, Kiura K, et al
    ASP8273 tolerability and antitumor activity in TKI-naive Japanese patients with EGFR mutation-positive non-small cell lung cancer.
    Cancer Sci. 2018 May 28. doi: 10.1111/cas.13651.
    PubMed     Text format     Abstract available


  8. LI S, Ma F, Jiang K, Shan H, et al
    Long non-coding RNA metastasis-associated lung adenocarcinoma transcript 1 promotes lung adenocarcinoma by directly interacting with specificity protein 1.
    Cancer Sci. 2018;109:1346-1356.
    PubMed     Text format     Abstract available


  9. LIU K, Gao H, Wang Q, Wang L, et al
    Hispidulin suppresses cell growth and metastasis by targeting PIM1 through JAK2/STAT3 signaling in colorectal cancer.
    Cancer Sci. 2018;109:1369-1381.
    PubMed     Text format     Abstract available


  10. SEMBA T, Sugihara E, Kamoshita N, Ueno S, et al
    Periostin antisense oligonucleotide suppresses bleomycin-induced formation of a lung premetastatic niche for melanoma.
    Cancer Sci. 2018;109:1447-1454.
    PubMed     Text format     Abstract available


  11. HAYASHI K, Yamamoto N, Karube M, Nakajima M, et al
    Feasibility of carbon-ion radiotherapy for re-irradiation of locoregionally recurrent, metastatic, or secondary lung tumors.
    Cancer Sci. 2018;109:1562-1569.
    PubMed     Text format     Abstract available


    April 2018
  12. AKAMATSU H, Katakami N, Okamoto I, Kato T, et al
    Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small cell lung cancer: AURA3 trial.
    Cancer Sci. 2018 Apr 26. doi: 10.1111/cas.13623.
    PubMed     Text format     Abstract available


  13. WANG Y, Lei L, Zheng YW, Zhang L, et al
    Odd-skipped related 1 inhibits lung cancer proliferation and invasion by reducing Wnt signaling through the suppression of SOX9 and beta-catenin.
    Cancer Sci. 2018 Apr 16. doi: 10.1111/cas.13614.
    PubMed     Text format     Abstract available


  14. TANAKA I, Sato M, Kato T, Goto D, et al
    eIF2beta, a Subunit of Translation-Initiation Factor EIF2, Is a Potential Therapeutic Target for Non-Small Cell Lung Cancer.
    Cancer Sci. 2018 Apr 6. doi: 10.1111/cas.13602.
    PubMed     Text format     Abstract available


    March 2018
  15. WANG N, Song X, Liu L, Niu L, et al
    Circulating exosomes contain protein biomarkers of metastatic non-small-cell lung cancer.
    Cancer Sci. 2018 Mar 23. doi: 10.1111/cas.13581.
    PubMed     Text format     Abstract available


  16. TORIGOE H, Shien K, Takeda T, Yoshioka T, et al
    Therapeutic strategies for afatinib-resistant lung cancer harboring HER2 alterations.
    Cancer Sci. 2018 Mar 13. doi: 10.1111/cas.13571.
    PubMed     Text format     Abstract available


    February 2018
  17. XU Y, Ren H, Jiang J, Wang Q, et al
    KIAA0247 inhibits growth, migration, invasion of non-small-cell lung cancer through regulating the Notch pathway.
    Cancer Sci. 2018 Feb 16. doi: 10.1111/cas.13539.
    PubMed     Text format     Abstract available


  18. LI W, Zheng G, Xia J, Yang G, et al
    CREPT overexpression is associated with proliferation behaviors and poor prognosis in non-small cell lung cancer.
    Cancer Sci. 2018 Feb 3. doi: 10.1111/cas.13524.
    PubMed     Text format     Abstract available


  19. OHARA Y, Chew SH, Shibata T, Okazaki Y, et al
    Phlebotomy as a preventive measure for crocidolite-induced mesothelioma in male rats.
    Cancer Sci. 2018;109:330-339.
    PubMed     Text format     Abstract available


  20. LI P, Zhang L, Yu X, Tong R, et al
    Proliferation genes in lung development associated with the prognosis of lung adenocarcinoma but not squamous cell carcinoma.
    Cancer Sci. 2018;109:308-316.
    PubMed     Text format     Abstract available


    January 2018
  21. ZHANG Q, Yang J, Bai J, Ren J, et al
    Reverse of non-small cell lung cancer drug resistance induced by cancer associated fibroblasts via a paracrine pathway.
    Cancer Sci. 2018 Jan 30. doi: 10.1111/cas.13520.
    PubMed     Text format     Abstract available


  22. KIURA K, Yoh K, Katakami N, Nogami N, et al
    Osimertinib in patients with EGFR T790M advanced non-small cell lung cancer selected using cytology samples.
    Cancer Sci. 2018 Jan 24. doi: 10.1111/cas.13511.
    PubMed     Text format     Abstract available


  23. CHARVAT H, Sasazuki S, Shimazu T, Budhathoki S, et al
    Development of a risk prediction model for lung cancer: the Japan Public Health Center-based Prospective Study.
    Cancer Sci. 2018 Jan 18. doi: 10.1111/cas.13509.
    PubMed     Text format     Abstract available


  24. KATAYAMA R
    Drug resistance in anaplastic lymphoma kinase-rearranged lung cancer.
    Cancer Sci. 2018 Jan 16. doi: 10.1111/cas.13504.
    PubMed     Text format     Abstract available


  25. FAZIO N, Buzzoni R, Delle Fave G, Tesselaar ME, et al
    Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis.
    Cancer Sci. 2018;109:174-181.
    PubMed     Text format     Abstract available


    December 2017
  26. CHENG HW, Chein RJ, Cheng TJ, Wu PS, et al
    The 2-anilino-4-amino-5-aroylthiazole-type compound AS7128 inhibits lung cancer growth through decreased iASPP and p53 interaction.
    Cancer Sci. 2017 Dec 29. doi: 10.1111/cas.13489.
    PubMed     Text format     Abstract available


    November 2017
  27. LIU J, Bian T, Feng J, Qian L, et al
    miR-335 inhibited cell proliferation of lung cancer cells by target Tra2beta.
    Cancer Sci. 2017 Nov 21. doi: 10.1111/cas.13452.
    PubMed     Text format     Abstract available


  28. ESAKI N, Ohkawa Y, Hashimoto N, Tsuda Y, et al
    ASCT2 defined by enzyme-mediated activation of radical sources enhances malignancy of GD2-plus small cell lung cancer.
    Cancer Sci. 2017 Nov 19. doi: 10.1111/cas.13448.
    PubMed     Text format     Abstract available


  29. OKABE H, Aoki K, Yogosawa S, Saito M, et al
    Downregulation of CD24 suppresses bone metastasis of lung cancer.
    Cancer Sci. 2017 Nov 2. doi: 10.1111/cas.13435.
    PubMed     Text format     Abstract available


  30. MAGARA K, Takasawa A, Osanai M, Ota M, et al
    Elevated expression of JAM-A promotes neoplastic properties of lung adenocarcinoma.
    Cancer Sci. 2017;108:2306-2314.
    PubMed     Text format     Abstract available


  31. DASSANO A, Pintarelli G, Cotroneo CE, Pettinicchio A, et al
    Complex genetic control of lung tumorigenesis in resistant mice strains.
    Cancer Sci. 2017;108:2281-2286.
    PubMed     Text format     Abstract available


    October 2017
  32. KATSURA M, Shoji F, Okamoto T, Shimamatsu S, et al
    Correlation between CXCR4/CXCR7/CXCL12 chemokine axis expression and prognosis in lymph-node-positive lung cancer patients.
    Cancer Sci. 2017 Oct 15. doi: 10.1111/cas.13422.
    PubMed     Text format     Abstract available


  33. HUANG LX, Hu CY, Jing L, Wang MC, et al
    microRNA-219-5p inhibits epithelial-mesenchymal transition and metastasis of colorectal cancer by targeting lymphoid enhancer-binding factor 1.
    Cancer Sci. 2017;108:1985-1995.
    PubMed     Text format     Abstract available


  34. TAKITA J
    The role of anaplastic lymphoma kinase in pediatric cancers.
    Cancer Sci. 2017;108:1913-1920.
    PubMed     Text format     Abstract available


    September 2017
  35. LIU L, Liu J, Shao D, Deng Q, et al
    Comprehensive genomic profiling of lung cancer using a validated panel to explore therapeutic targets in East Asian patients.
    Cancer Sci. 2017 Sep 26. doi: 10.1111/cas.13410.
    PubMed     Text format     Abstract available


  36. CHI Y, Jin Q, Liu X, Xu L, et al
    The miR-203 inhibits cell proliferation, invasion, and migration of non-small cell lung cancer by downregulating RGS17.
    Cancer Sci. 2017 Sep 16. doi: 10.1111/cas.13401.
    PubMed     Text format     Abstract available


  37. MATSUBARA D, Soda M, Yoshimoto T, Amano Y, et al
    Inactivating mutations and hypermethylation of the NKX2-1/TTF-1 gene in non-terminal respiratory unit-type lung adenocarcinomas.
    Cancer Sci. 2017;108:1888-1896.
    PubMed     Text format     Abstract available


    August 2017
  38. KUTKOWSKA J, Strzadala L, Rapak A
    Synergistic activity of sorafenib and betulinic acid against clonogenic activity of non-small cell lung cancer cells.
    Cancer Sci. 2017 Aug 28. doi: 10.1111/cas.13386.
    PubMed     Text format     Abstract available


  39. INOUE Y, Matsuura S, Yoshimura K, Iwashita Y, et al
    Characterization of V-set and immunoglobulin domain containing 1 exerting a tumor suppressor function in gastric, lung, and esophageal cancer cells.
    Cancer Sci. 2017;108:1701-1714.
    PubMed     Text format     Abstract available


    July 2017
  40. OTSUBO K, Nosaki K, Imamura CK, Ogata H, et al
    Phase I study of salazosulfapyridine in combination with cisplatin and pemetrexed for advanced non-small cell lung cancer.
    Cancer Sci. 2017 Jul 1. doi: 10.1111/cas.13309.
    PubMed     Text format     Abstract available


  41. GRIESING S, Kajino T, Tai MC, Liu Z, et al
    Thyroid transcription factor-1-regulated microRNA-532-5p targets KRAS and MKL2 oncogenes and induces apoptosis in lung adenocarcinoma cells.
    Cancer Sci. 2017;108:1394-1404.
    PubMed     Text format     Abstract available


  42. KUNIMASA K, Nagano T, Shimono Y, Dokuni R, et al
    Glucose metabolism-targeted therapy and withaferin A are effective for epidermal growth factor receptor tyrosine kinase inhibitor-induced drug-tolerant persisters.
    Cancer Sci. 2017;108:1368-1377.
    PubMed     Text format     Abstract available


    May 2017
  43. TANIGUCHI H, Yamada T, Takeuchi S, Arai S, et al
    The impact of MET inhibition on small-cell lung cancer cells exhibiting aberrant activation of the HGF/MET pathway.
    Cancer Sci. 2017 May 5. doi: 10.1111/cas.13268.
    PubMed     Text format     Abstract available


    April 2017
  44. WANG R, Deng X, Yoshioka Y, Vougiouklakis T, et al
    Effects of SMYD2-mediated EML4-ALK methylation on the signaling pathway and growth in non-small cell lung cancer cells.
    Cancer Sci. 2017 Apr 1. doi: 10.1111/cas.13245.
    PubMed     Text format     Abstract available


    March 2017
  45. TODE N, Kikuchi T, Sakakibara T, Hirano T, et al
    Exome sequencing deciphers a germline MET mutation in familial epidermal growth factor receptor-mutant lung cancer.
    Cancer Sci. 2017 Mar 13. doi: 10.1111/cas.13233.
    PubMed     Text format     Abstract available


  46. HIDA T, Nishio M, Nogami N, Ohe Y, et al
    Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non-small cell lung cancer.
    Cancer Sci. 2017 Mar 7. doi: 10.1111/cas.13225.
    PubMed     Text format     Abstract available


  47. SATO T, Shiba-Ishii A, Kim Y, Dai T, et al
    miR-3941: A novel microRNA that controls IGBP1 expression and is associated with malignant progression of lung adenocarcinoma.
    Cancer Sci. 2017;108:536-542.
    PubMed     Text format     Abstract available


  48. KUSUMOTO H, Shintani Y, Kanzaki R, Kawamura T, et al
    Podocalyxin influences malignant potential by controlling epithelial-mesenchymal transition in lung adenocarcinoma.
    Cancer Sci. 2017;108:528-535.
    PubMed     Text format     Abstract available


    February 2017
  49. KAKUMU T, Sato M, Goto D, Kato T, et al
    Identification of Proteasomal Catalytic Subunit PSMA6 as a Therapeutic Target for Lung Cancer.
    Cancer Sci. 2017 Feb 6. doi: 10.1111/cas.13185.
    PubMed     Text format     Abstract available


  50. KAMIOKA Y, Takakura K, Sumiyama K, Matsuda M, et al
    Intravital Forster resonance energy transfer imaging reveals osteopontin-mediated polymorphonuclear leukocyte activation by tumor cell emboli.
    Cancer Sci. 2017;108:226-235.
    PubMed     Text format     Abstract available


  51. KARASAKI T, Nagayama K, Kuwano H, Nitadori JI, et al
    Prediction and prioritization of neoantigens: integration of RNA sequencing data with whole-exome sequencing.
    Cancer Sci. 2017;108:170-177.
    PubMed     Text format     Abstract available


    January 2017
  52. PARK JH, Inoue H, Kato T, Zewde M, et al
    TOPK (T-LAK cell-originated protein kinase) inhibitor exhibits growth suppressive effect on small cell lung cancer.
    Cancer Sci. 2017 Jan 11. doi: 10.1111/cas.13160.
    PubMed     Text format     Abstract available


  53. HARADA A, Uchino J, Harada T, Nakagaki N, et al
    Vascular endothelial growth factor promoter-based conditionally replicative adenoviruses effectively suppress growth of malignant pleural mesothelioma.
    Cancer Sci. 2017;108:116-123.
    PubMed     Text format     Abstract available


  54. IKEMURA S, Aramaki N, Fujii S, Kirita K, et al
    Changes in the tumor microenvironment during lymphatic metastasis of lung squamous cell carcinoma.
    Cancer Sci. 2017;108:136-142.
    PubMed     Text format     Abstract available


    December 2016
  55. CHEN Y, Yang J, Li X, Hao D, et al
    First-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor alone or with whole-brain radiotherapy for brain metastases in patients with EGFR-mutated lung adenocarcinoma.
    Cancer Sci. 2016;107:1800-1805.
    PubMed     Text format     Abstract available


    November 2016
  56. HIBI M, Kaneda H, Tanizaki J, Sakai K, et al
    FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib.
    Cancer Sci. 2016;107:1667-1676.
    PubMed     Text format     Abstract available


  57. HIDA T, Nakagawa K, Seto T, Satouchi M, et al
    Pharmacologic study (JP28927) of alectinib in Japanese patients with ALK+ non-small-cell lung cancer with or without prior crizotinib therapy.
    Cancer Sci. 2016;107:1642-1646.
    PubMed     Text format     Abstract available


    October 2016
  58. TANIGUCHI H, Takeuchi S, Fukuda K, Nakagawa T, et al
    AREG triggered EGFR activation confers in vivo crizotinib-resistance of EML4-ALK lung cancer and circumvention by EGFR inhibitors.
    Cancer Sci. 2016 Oct 26. doi: 10.1111/cas.13111.
    PubMed     Text format     Abstract available


  59. GOTO K, Endo M, Kusumoto M, Yamamoto N, et al
    Bevacizumab for non-small-cell lung cancer: A nested case control study of risk factors for hemoptysis.
    Cancer Sci. 2016 Oct 6. doi: 10.1111/cas.13096.
    PubMed     Text format     Abstract available


  60. KATO S, Yokoyama S, Hayakawa Y, Li L, et al
    P38 pathway as a key downstream signal of connective tissue growth factor to regulate metastatic potential in non-small-cell lung cancer.
    Cancer Sci. 2016;107:1416-1421.
    PubMed     Text format     Abstract available


  61. ITO T, Matsubara D, Tanaka I, Makiya K, et al
    Loss of YAP1 defines neuroendocrine differentiation of lung tumors.
    Cancer Sci. 2016;107:1527-1538.
    PubMed     Text format     Abstract available


    September 2016
  62. MIYAZAKI K, Oyanagi J, Sugino A, Sato H, et al
    Highly sensitive detection of invasive lung cancer cells by novel antibody against amino-terminal domain of laminin gamma2 chain.
    Cancer Sci. 2016 Sep 29. doi: 10.1111/cas.13089.
    PubMed     Text format     Abstract available


  63. HORIE M, Saito A, Ohshima M, Suzuki HI, et al
    YAP and TAZ modulate cell phenotype in a subset of small cell lung cancer.
    Cancer Sci. 2016 Sep 14. doi: 10.1111/cas.13078.
    PubMed     Text format     Abstract available


  64. ZHANG P, Ma Y, Lv C, Huang M, et al
    The up-regulation of PD-L1 promotes the resistant response in non-small cell lung cancer patients with neo-adjuvant chemotherapy.
    Cancer Sci. 2016 Sep 1. doi: 10.1111/cas.13072.
    PubMed     Text format     Abstract available


  65. SUNADA S, Kanai H, Lee Y, Yasuda T, et al
    Nontoxic concentration of DNA-PK inhibitor NU7441 radio-sensitizes lung tumor cells with little effect on double strand break repair.
    Cancer Sci. 2016;107:1250-5.
    PubMed     Text format     Abstract available


  66. ABE S, Kaneko MK, Tsuchihashi Y, Izumi T, et al
    Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in an orthotopic xenograft model.
    Cancer Sci. 2016;107:1198-205.
    PubMed     Text format     Abstract available


    August 2016
  67. OHIRA T, Sakai K, Matsubayashi J, Kajiwara N, et al
    Tumor volume determines the feasibility of cell-free DNA sequencing for mutation detection in non-small cell lung cancer.
    Cancer Sci. 2016 Aug 30. doi: 10.1111/cas.13068.
    PubMed     Text format     Abstract available


  68. WANG XZ, Cheng Y, Wang KL, Liu R, et al
    Peperomin E reactivates silenced tumor suppressor genes in lung cancer cells via inhibition of DNA methyltransferase.
    Cancer Sci. 2016 Aug 8. doi: 10.1111/cas.13029.
    PubMed     Text format     Abstract available


  69. FUJIWARA Y, Hamada A, Mizugaki H, Aikawa H, et al
    Pharmacokinetic profiles of significant adverse events with crizotinib in Japanese patients with ABCB1 polymorphism.
    Cancer Sci. 2016;107:1117-23.
    PubMed     Text format     Abstract available


    July 2016
  70. SUZUI M, Futakuchi M, Fukamachi K, Numano T, et al
    Multiwalled carbon nanotubes intratracheally instilled into the rat lung induce development of pleural malignant mesothelioma and lung tumors.
    Cancer Sci. 2016;107:924-35.
    PubMed     Text format     Abstract available


    June 2016
  71. KOBAYASHI Y, Mitsudomi T
    Not all EGFR mutations in lung cancer are created equal: Perspectives for individualized treatment strategy.
    Cancer Sci. 2016 Jun 20. doi: 10.1111/cas.12996.
    PubMed     Text format     Abstract available


  72. SAITO M, Shiraishi K, Kunitoh H, Takenoshita S, et al
    Gene aberrations for precision medicine against lung adenocarcinoma.
    Cancer Sci. 2016;107:713-20.
    PubMed     Text format     Abstract available


    May 2016
  73. KAWAMURA T, Kenmotsu H, Taira T, Omori S, et al
    Rebiopsy for Patients with Non-Small-Cell Lung Cancer after Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Failure.
    Cancer Sci. 2016 May 4. doi: 10.1111/cas.12963.
    PubMed     Text format     Abstract available


    April 2016
  74. TAKASHINA T, Kinoshita I, Kikuchi J, Shimizu Y, et al
    Combined inhibition of EZH2 and HDACs as a potential epigenetic therapy for non-small cell lung cancer cells.
    Cancer Sci. 2016 Apr 26. doi: 10.1111/cas.12957.
    PubMed     Text format     Abstract available


  75. HARADA H, Fuji H, Ono A, Kenmotsu H, et al
    Dose escalation study of proton beam therapy with concurrent chemotherapy for stage III non-small cell lung cancer.
    Cancer Sci. 2016 Apr 25. doi: 10.1111/cas.12955.
    PubMed     Text format     Abstract available


  76. PAISIE CA, Schrock MS, Karras JR, Zhang J, et al
    Exome-wide single-base substitutions in tissues and derived cell lines of the constitutive Fhit knockout mouse.
    Cancer Sci. 2016;107:528-35.
    PubMed     Text format     Abstract available


  77. GUO Z, Cao M, You A, Gao J, et al
    Metformin inhibits the prometastatic effect of sorafenib in hepatocellular carcinoma by upregulating the expression of TIP30.
    Cancer Sci. 2016;107:507-13.
    PubMed     Text format     Abstract available


    March 2016
  78. ZHANG F, Duan S, Tsai Y, Keng P, et al
    Cisplatin treatment increases stemness via up-regulation of hypoxia inducible factors by IL-6 in non-small cell lung cancer.
    Cancer Sci. 2016 Mar 24. doi: 10.1111/cas.12937.
    PubMed     Text format     Abstract available


  79. TAKAOKA S, Kamioka Y, Takakura K, Baba A, et al
    Live imaging of TAK1 activation in Lewis lung carcinoma 3LL cells implanted into syngeneic mice and treated with polyI:C.
    Cancer Sci. 2016 Mar 2. doi: 10.1111/cas.12923.
    PubMed     Text format     Abstract available


  80. PARK SY, Korm S, Chung HJ, Choi SJ, et al
    RAP80 regulates epithelial-mesenchymal transition related with metastasis and malignancy of cancer.
    Cancer Sci. 2016;107:267-73.
    PubMed     Text format     Abstract available


  81. SAWADA T, Watanabe M, Fujimura Y, Yagishita S, et al
    Sensitive cytometry based system for enumeration, capture and analysis of gene mutations of circulating tumor cells.
    Cancer Sci. 2016;107:307-14.
    PubMed     Text format     Abstract available


  82. UCHIDA J, Imamura F, Kukita Y, Oba S, et al
    Dynamics of circulating tumor DNA represented by the activating and resistant mutations in epidermal growth factor receptor tyrosine kinase inhibitor treatment.
    Cancer Sci. 2016;107:353-8.
    PubMed     Text format     Abstract available


    February 2016
  83. MIZUUCHI H, Suda K, Murakami I, Sakai K, et al
    Oncogene swap as a novel mechanism of acquired resistance to EGFR-tyrosine kinase inhibitor in lung cancer.
    Cancer Sci. 2016 Feb 4. doi: 10.1111/cas.12905.
    PubMed     Text format     Abstract available


  84. YAMANO S, Gi M, Tago Y, Doi K, et al
    Role of deltaNp63(pos)CD44v(pos) cells in the development of N-nitroso-tris-chloroethylurea-induced peripheral-type mouse lung squamous cell carcinomas.
    Cancer Sci. 2016;107:123-32.
    PubMed     Text format     Abstract available


  85. IDA L, Yamaguchi T, Yanagisawa K, Kajino T, et al
    Receptor tyrosine kinase-like orphan receptor 1, a target of NKX2-1/TTF-1 lineage-survival oncogene, inhibits apoptosis signal-regulating kinase 1-mediated pro-apoptotic signaling in lung adenocarcinoma.
    Cancer Sci. 2016;107:155-61.
    PubMed     Text format     Abstract available


    January 2016
  86. MISUMI K, Sun J, Kinomura A, Miyata Y, et al
    Enhanced gefitinib-induced repression of the EGFR pathway by ATM kinase inhibition in non-small cell lung cancer cells.
    Cancer Sci. 2016 Jan 30. doi: 10.1111/cas.12899.
    PubMed     Text format     Abstract available


  87. OTA M, Mochizuki S, Shimoda M, Abe H, et al
    ADAM23 is down-regulated in side population and suppresses lung metastasis of lung carcinoma cells.
    Cancer Sci. 2016 Jan 22. doi: 10.1111/cas.12895.
    PubMed     Text format     Abstract available


  88. SAITO Y, Nagae G, Motoi N, Miyauchi E, et al
    Prognostic significance of CpG island methylator phenotype in surgically resected small cell lung carcinoma.
    Cancer Sci. 2016 Jan 7. doi: 10.1111/cas.12876.
    PubMed     Text format     Abstract available


  89. SEKINE I, Sumi M, Satouchi M, Tsujino K, et al
    Feasibility study of chemoradiotherapy followed by amrubicin and cisplatin for limited-disease small cell lung cancer.
    Cancer Sci. 2016 Jan 7. doi: 10.1111/cas.12875.
    PubMed     Text format     Abstract available


  90. SUZAWA K, Toyooka S, Sakaguchi M, Morita M, et al
    Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.
    Cancer Sci. 2016;107:45-52.
    PubMed     Text format     Abstract available


    November 2015
  91. SUEOKA-ARAGANE N, Katakami N, Satouchi M, Yokota S, et al
    Monitoring EGFR T790M with plasma DNA from lung cancer patients in a prospective observational study.
    Cancer Sci. 2015 Nov 17. doi: 10.1111/cas.12847.
    PubMed     Text format     Abstract available


    October 2015
  92. WANG Z, Luo Z, Zhou L, Li X, et al
    DDX5 promotes proliferation and tumorigenesis of non-small-cell lung cancer cells by activating beta-catenin signaling pathway.
    Cancer Sci. 2015;106:1303-12.
    PubMed     Text format     Abstract available


  93. MINAMI D, Takigawa N, Kato Y, Kudo K, et al
    Downregulation of TBXAS1 in an iron-induced malignant mesothelioma model.
    Cancer Sci. 2015;106:1296-302.
    PubMed     Text format     Abstract available


    September 2015
  94. DING M, Li R, He R, Wang X, et al
    p53 activated by AND gate genetic circuit under radiation and hypoxia for targeted cancer gene therapy.
    Cancer Sci. 2015;106:1163-73.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: